Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

The transcriptome of peripheral blood mononuclear cells in patients with clinical subtypes of late age-related macular degeneration.

Subhi Y, Nielsen MK, Molbech CR, Liisborg C, Søndergaard HB, Sellebjerg F, Sørensen TL.

Immun Ageing. 2019 Aug 15;16:20. doi: 10.1186/s12979-019-0160-0. eCollection 2019.

2.

Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 2008‒2018: A nationwide, population-based cohort study.

Boesen MS, Jensen PEH, Born AP, Magyari M, Nilsson AC, Hoei-Hansen C, Blinkenberg M, Sellebjerg F.

Mult Scler Relat Disord. 2019 Aug;33:162-167. doi: 10.1016/j.msard.2019.06.002. Epub 2019 Jun 5.

PMID:
31276927
3.

Relationship between Multiple Sclerosis-Associated IL2RA Risk Allele Variants and Circulating T Cell Phenotypes in Healthy Genotype-Selected Controls.

Buhelt S, Søndergaard HB, Oturai A, Ullum H, von Essen MR, Sellebjerg F.

Cells. 2019 Jun 25;8(6). pii: E634. doi: 10.3390/cells8060634.

4.

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL Group, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ.

JAMA Neurol. 2019 Jun 17. doi: 10.1001/jamaneurol.2019.1534. [Epub ahead of print]

PMID:
31206160
5.

Illegal cannabis use is common among Danes with multiple sclerosis.

Gustavsen S, Søndergaard HB, Andresen SR, Magyari M, Sørensen PS, Sellebjerg F, Oturai AB.

Mult Scler Relat Disord. 2019 Aug;33:5-12. doi: 10.1016/j.msard.2019.05.008. Epub 2019 May 16.

PMID:
31129415
6.

Diagnostic Value of Oligoclonal Bands in Children: A Nationwide Population-Based Cohort Study.

Boesen MS, Born AP, Jensen PEH, Sellebjerg F, Blinkenberg M, Lydolph MC, Jørgensen MK, Rosenberg L, Thomassen JQ, Børresen ML.

Pediatr Neurol. 2019 Aug;97:56-63. doi: 10.1016/j.pediatrneurol.2019.03.002. Epub 2019 Mar 13.

PMID:
31060768
7.

Pulsed immune reconstitution therapy in multiple sclerosis.

Sorensen PS, Sellebjerg F.

Ther Adv Neurol Disord. 2019 Mar 28;12:1756286419836913. doi: 10.1177/1756286419836913. eCollection 2019. Review.

8.

IL-6, IL-12, and IL-23 STAT-Pathway Genetic Risk and Responsiveness of Lymphocytes in Patients with Multiple Sclerosis.

von Essen MR, Søndergaard HB, Petersen ERS, Sellebjerg F.

Cells. 2019 Mar 26;8(3). pii: E285. doi: 10.3390/cells8030285.

9.

Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study.

Buron MD, Chalmer TA, Sellebjerg F, Frederiksen J, Góra MK, Illes Z, Kant M, Mezei Z, Petersen T, Rasmussen PV, Roshanisefat H, Hassanpour-Kalam-Roudy H, Sejbæk T, Tsakiri A, Weglewski A, Sorensen PS, Magyari M.

Neurology. 2019 Apr 16;92(16):e1811-e1820. doi: 10.1212/WNL.0000000000007314. Epub 2019 Mar 15.

PMID:
30877188
10.

Perfluorinated substances, risk factors for multiple sclerosis and cellular immune activation.

Ammitzbøll C, Börnsen L, Petersen ER, Oturai AB, Søndergaard HB, Grandjean P, Sellebjerg F.

J Neuroimmunol. 2019 May 15;330:90-95. doi: 10.1016/j.jneuroim.2019.03.002. Epub 2019 Mar 2.

11.

Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis.

von Essen MR, Ammitzbøll C, Hansen RH, Petersen ERS, McWilliam O, Marquart HV, Damm P, Sellebjerg F.

Brain. 2019 Jan 1;142(1):120-132. doi: 10.1093/brain/awy301.

PMID:
30561509
12.

The neutrophil-to-lymphocyte ratio is associated with multiple sclerosis.

Hasselbalch IC, Søndergaard HB, Koch-Henriksen N, Olsson A, Ullum H, Sellebjerg F, Oturai AB.

Mult Scler J Exp Transl Clin. 2018 Nov 28;4(4):2055217318813183. doi: 10.1177/2055217318813183. eCollection 2018 Oct-Dec.

13.

Structural and cognitive correlates of fatigue in progressive multiple sclerosis.

Andreasen AK, Iversen P, Marstrand L, Siersma V, Siebner HR, Sellebjerg F.

Neurol Res. 2019 Feb;41(2):168-176. doi: 10.1080/01616412.2018.1547813. Epub 2018 Dec 4.

PMID:
30513278
14.

Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.

Jensen PEH, Warnke C, Ingenhoven K, Piccoli L, Gasis M, Hermanrud C, Fernandez-Rodriguez BM, Ryner M, Kramer D, Link J, Ramanujam R, Auer M, Buck D, Grummel V, Bertotti E, Fissolo N, Oliver-Martos B, Nytrova P, Khalil M, Guger M, Rathmaier S, Sievers-Stober C, Lindberg RLP, Hässler S, Bachelet D, Aktas O, Donnellan N, Lawton A, Hemmer B, Havrdova EK, Kieseier B, Hartung HP, Comabella M, Montalban X, Derfuss T, Sellebjerg F, Dönnes P, Pallardy M, Spindeldreher S, Broët P, Deisenhammer F, Fogdell-Hahn A, Sorensen PS; ABIRISK Consortium.

J Neuroimmunol. 2019 Jan 15;326:19-27. doi: 10.1016/j.jneuroim.2018.11.002. Epub 2018 Nov 7.

PMID:
30447419
15.

Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark.

Papp V, Illes Z, Magyari M, Koch-Henriksen N, Kant M, Pfleger CC, Roemer SF, Jensen MB, Petersen AE, Nielsen HH, Rosendahl L, Mezei Z, Christensen T, Svendsen K, Hyldgaard Jensen PE, Lydolph MC, Heegaard N, Frederiksen JL, Sellebjerg F, Stenager E, Petersen T.

Neurology. 2018 Dec 11;91(24):e2265-e2275. doi: 10.1212/WNL.0000000000006645. Epub 2018 Nov 9.

16.

GPR15+ T cells are Th17 like, increased in smokers and associated with multiple sclerosis.

Ammitzbøll C, von Essen MR, Börnsen L, Petersen ER, McWilliam O, Ratzer R, Romme Christensen J, Oturai AB, Søndergaard HB, Sellebjerg F.

J Autoimmun. 2019 Feb;97:114-121. doi: 10.1016/j.jaut.2018.09.005. Epub 2018 Sep 21.

PMID:
30245027
17.

B cells from patients with multiple sclerosis have a pathogenic phenotype and increased LTα and TGFβ1 response.

McWilliam O, Sellebjerg F, Marquart HV, von Essen MR.

J Neuroimmunol. 2018 Nov 15;324:157-164. doi: 10.1016/j.jneuroim.2018.09.001. Epub 2018 Sep 7.

PMID:
30244922
18.

Clinical utility of anti-MOG antibody testing in a Danish cohort.

Papp V, Langkilde AR, Blinkenberg M, Schreiber K, Jensen PEH, Sellebjerg F.

Mult Scler Relat Disord. 2018 Nov;26:61-67. doi: 10.1016/j.msard.2018.09.010. Epub 2018 Sep 11.

PMID:
30227311
19.

Inflammatory markers of CHMP2B-mediated frontotemporal dementia.

Roos P, von Essen MR, Nielsen TT, Johannsen P, Stokholm J, Bie AS, Waldemar G, Simonsen AH, Heslegrave A, Zetterberg H; FReJA consortium, Sellebjerg F, Nielsen JE.

J Neuroimmunol. 2018 Nov 15;324:136-142. doi: 10.1016/j.jneuroim.2018.08.009. Epub 2018 Aug 17.

PMID:
30193769
20.

Alcohol consumption in adolescence is associated with a lower risk of multiple sclerosis in a Danish cohort.

Andersen C, Søndergaard HB, Bang Oturai D, Laursen JH, Gustavsen S, Larsen NK, Magyari M, Just-Østergaard E, Thørner LW, Sellebjerg F, Ullum H, Oturai AB.

Mult Scler. 2018 Aug 20:1352458518795418. doi: 10.1177/1352458518795418. [Epub ahead of print]

PMID:
30124094
21.

Orthologous proteins of experimental de- and remyelination are differentially regulated in the CSF proteome of multiple sclerosis subtypes.

Martin NA, Nawrocki A, Molnar V, Elkjaer ML, Thygesen EK, Palkovits M, Acs P, Sejbaek T, Nielsen HH, Hegedus Z, Sellebjerg F, Molnar T, Barbosa EGV, Alcaraz N, Gallyas F Jr, Svenningsen AF, Baumbach J, Lassmann H, Larsen MR, Illes Z.

PLoS One. 2018 Aug 16;13(8):e0202530. doi: 10.1371/journal.pone.0202530. eCollection 2018.

22.

Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.

Sellebjerg F, Royen L, Soelberg Sørensen P, Oturai AB, Jensen PEH.

Mult Scler. 2019 Oct;25(11):1444-1451. doi: 10.1177/1352458518794308. Epub 2018 Aug 16.

PMID:
30113249
23.

Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis.

Petersen ER, Søndergaard HB, Laursen JH, Olsson AG, Börnsen L, Soelberg Sørensen P, Sellebjerg F, Bang Oturai A.

Mult Scler. 2019 Aug;25(9):1298-1305. doi: 10.1177/1352458518791753. Epub 2018 Aug 2.

PMID:
30070595
24.

Increased cerebrospinal fluid chitinase 3-like 1 and neurofilament light chain in pediatric acquired demyelinating syndromes.

Boesen MS, Jensen PEH, Magyari M, Born AP, Uldall PV, Blinkenberg M, Sellebjerg F.

Mult Scler Relat Disord. 2018 Aug;24:175-183. doi: 10.1016/j.msard.2018.05.017. Epub 2018 Jun 11.

PMID:
30055504
25.

Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis.

Holm Hansen R, Højsgaard Chow H, Sellebjerg F, Rode von Essen M.

Mult Scler. 2019 Aug;25(9):1289-1297. doi: 10.1177/1352458518790417. Epub 2018 Jul 25.

PMID:
30043661
26.

CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.

Romme Christensen J, Komori M, von Essen MR, Ratzer R, Börnsen L, Bielekova B, Sellebjerg F.

Mult Scler. 2019 Jun;25(7):937-946. doi: 10.1177/1352458518774880. Epub 2018 May 18.

PMID:
29775134
27.

Functional neuroimaging of recovery from motor conversion disorder: A case report.

Dogonowski AM, Andersen KW, Sellebjerg F, Schreiber K, Madsen KH, Siebner HR.

Neuroimage. 2019 Apr 15;190:269-274. doi: 10.1016/j.neuroimage.2018.03.061. Epub 2018 Mar 27. Review.

28.

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators.

Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12.

PMID:
29545067
29.

Progressive multiple sclerosis, cognitive function, and quality of life.

Højsgaard Chow H, Schreiber K, Magyari M, Ammitzbøll C, Börnsen L, Romme Christensen J, Ratzer R, Soelberg Sørensen P, Sellebjerg F.

Brain Behav. 2018 Jan 5;8(2):e00875. doi: 10.1002/brb3.875. eCollection 2018 Feb.

30.

Smoking affects the interferon beta treatment response in multiple sclerosis.

Petersen ER, Oturai AB, Koch-Henriksen N, Magyari M, Sørensen PS, Sellebjerg F, Søndergaard HB.

Neurology. 2018 Feb 13;90(7):e593-e600. doi: 10.1212/WNL.0000000000004949. Epub 2018 Jan 17.

PMID:
29343473
31.

Prediction of natalizumab anti-drug antibodies persistency.

Deisenhammer F, Jank M, Lauren A, Sjödin A, Ryner M, Fogdell-Hahn A, Sievers C, Lindberg R, Jensen PE, Sellebjerg F, Christodoulou L, Birchler M, Pallardy M, Auer M, Liblau R; ABIRISK consortium.

Mult Scler. 2019 Mar;25(3):392-398. doi: 10.1177/1352458517753721. Epub 2018 Jan 16.

PMID:
29336205
32.

Disability in progressive MS is associated with T2 lesion changes.

Ammitzbøll C, Dyrby TB, Lyksborg M, Schreiber K, Ratzer R, Romme Christensen J, Iversen P, Magyari M, Garde E, Sørensen PS, Siebner HR, Sellebjerg F.

Mult Scler Relat Disord. 2018 Feb;20:73-77. doi: 10.1016/j.msard.2017.12.010. Epub 2017 Dec 18.

PMID:
29324249
33.

Bone microarchitecture and bone mineral density in multiple sclerosis.

Olsson A, Oturai AB, Søndergaard HB, Sellebjerg F, Oturai PS.

Acta Neurol Scand. 2018 Mar;137(3):363-369. doi: 10.1111/ane.12884. Epub 2017 Dec 21.

PMID:
29270986
34.

Defining active progressive multiple sclerosis.

Sellebjerg F, Börnsen L, Ammitzbøll C, Nielsen JE, Vinther-Jensen T, Hjermind LE, von Essen M, Ratzer RL, Soelberg Sørensen P, Romme Christensen J.

Mult Scler. 2017 Nov;23(13):1727-1735. doi: 10.1177/1352458517726592. Epub 2017 Aug 23.

PMID:
28831853
35.

Characterization of naïve, memory and effector T cells in progressive multiple sclerosis.

Nielsen BR, Ratzer R, Börnsen L, von Essen MR, Christensen JR, Sellebjerg F.

J Neuroimmunol. 2017 Sep 15;310:17-25. doi: 10.1016/j.jneuroim.2017.06.001. Epub 2017 Jun 3.

PMID:
28778440
36.

The interaction between smoking and HLA genes in multiple sclerosis: replication and refinement.

Hedström AK, Katsoulis M, Hössjer O, Bomfim IL, Oturai A, Sondergaard HB, Sellebjerg F, Ullum H, Thørner LW, Gustavsen MW, Harbo HF, Obradovic D, Gianfrancesco MA, Barcellos LF, Schaefer CA, Hillert J, Kockum I, Olsson T, Alfredsson L.

Eur J Epidemiol. 2017 Oct;32(10):909-919. doi: 10.1007/s10654-017-0250-2. Epub 2017 Jun 8.

37.

Relationship between soluble CD25 and gene expression in healthy individuals and patients with multiple sclerosis.

Buhelt S, Ratzer RL, Christensen JR, Börnsen L, Sellebjerg F, Søndergaard HB.

Cytokine. 2017 May;93:15-25. doi: 10.1016/j.cyto.2017.04.024. Epub 2017 May 13.

PMID:
28511943
38.

Genetic burden of MS risk variants distinguish patients from healthy individuals but are not associated with disease activity.

Søndergaard HB, Petersen ER, Magyari M, Sellebjerg F, Oturai AB.

Mult Scler Relat Disord. 2017 Apr;13:25-27. doi: 10.1016/j.msard.2017.01.015. Epub 2017 Jan 31.

PMID:
28427696
39.

Systemic frequencies of T helper 1 and T helper 17 cells in patients with age-related macular degeneration: A case-control study.

Singh A, Subhi Y, Krogh Nielsen M, Falk MK, Matzen SMH, Sellebjerg F, Sørensen TL.

Sci Rep. 2017 Apr 4;7(1):605. doi: 10.1038/s41598-017-00741-4.

40.

Smoking reduces circulating CD26hiCD161hi MAIT cells in healthy individuals and patients with multiple sclerosis.

Ammitzbøll C, Börnsen L, Romme Christensen J, Ratzer R, Romme Nielsen B, Søndergaard HB, von Essen MR, Sellebjerg F.

J Leukoc Biol. 2017 May;101(5):1211-1220. doi: 10.1189/jlb.3A0616-267R. Epub 2017 Feb 8.

PMID:
28179539
41.

Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis.

Petersen ER, Søndergaard HB, Oturai AB, Jensen P, Sorensen PS, Sellebjerg F, Börnsen L.

Mult Scler Relat Disord. 2016 Nov;10:66-72. doi: 10.1016/j.msard.2016.09.001. Epub 2016 Sep 6.

PMID:
27919501
42.

Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab.

Laursen JH, Søndergaard HB, Sørensen PS, Sellebjerg F, Oturai AB.

Mult Scler Relat Disord. 2016 Nov;10:169-173. doi: 10.1016/j.msard.2016.10.005. Epub 2016 Oct 26.

PMID:
27919484
43.

Early safety and efficacy of fingolimod treatment in Denmark.

Voldsgaard A, Koch-Henriksen N, Magyari M, Sellebjerg F, Sørensen PS, Oturai AB.

Acta Neurol Scand. 2017 Jan;135(1):129-133. doi: 10.1111/ane.12573. Epub 2016 Mar 8.

PMID:
27910101
44.

Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease.

Vinther-Jensen T, Börnsen L, Budtz-Jørgensen E, Ammitzbøll C, Larsen IU, Hjermind LE, Sellebjerg F, Nielsen JE.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 28;3(6):e287. eCollection 2016 Dec.

45.

Shift work at young age is associated with increased risk of multiple sclerosis in a Danish population.

Gustavsen S, Søndergaard HB, Oturai DB, Laursen B, Laursen JH, Magyari M, Ullum H, Larsen MH, Sellebjerg F, Oturai AB.

Mult Scler Relat Disord. 2016 Sep;9:104-9. doi: 10.1016/j.msard.2016.06.010. Epub 2016 Jun 27.

PMID:
27645354
46.

Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.

George MF, Briggs FB, Shao X, Gianfrancesco MA, Kockum I, Harbo HF, Celius EG, Bos SD, Hedström A, Shen L, Bernstein A, Alfredsson L, Hillert J, Olsson T, Patsopoulos NA, De Jager PL, Oturai AB, Søndergaard HB, Sellebjerg F, Sorensen PS, Gomez R, Caillier SJ, Cree BA, Oksenberg JR, Hauser SL, D'Alfonso S, Leone MA, Martinelli Boneschi F, Sorosina M, van der Mei I, Taylor BV, Zhou Y, Schaefer C, Barcellos LF.

Neurol Genet. 2016 Aug 4;2(4):e87. doi: 10.1212/NXG.0000000000000087. eCollection 2016 Aug.

47.

High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.

Schreiber K, Magyari M, Sellebjerg F, Iversen P, Garde E, Madsen CG, Börnsen L, Romme Christensen J, Ratzer R, Siebner HR, Laursen B, Soelberg Sorensen P.

Mult Scler. 2017 Apr;23(5):675-685. doi: 10.1177/1352458516661048. Epub 2016 Aug 5.

PMID:
27481206
48.

Absence of systemic oxidative stress and increased CSF prostaglandin F2α in progressive MS.

Lam MA, Maghzal GJ, Khademi M, Piehl F, Ratzer R, Romme Christensen J, Sellebjerg FT, Olsson T, Stocker R.

Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(4):e256. doi: 10.1212/NXI.0000000000000256. eCollection 2016 Aug.

49.

Neurofilament in CSF-A biomarker of disease activity and long-term prognosis in multiple sclerosis.

Soelberg Sorensen P, Sellebjerg F.

Mult Scler. 2016 Aug;22(9):1112-3. doi: 10.1177/1352458516658560. Epub 2016 Jun 30. No abstract available.

PMID:
27364323
50.

A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.

Koch-Henriksen N, Magyari M, Sellebjerg F, Soelberg Sørensen P.

Mult Scler. 2017 Feb;23(2):234-241. doi: 10.1177/1352458516643393. Epub 2016 Jul 11.

PMID:
27055806

Supplemental Content

Loading ...
Support Center